Zobrazeno 1 - 10
of 195
pro vyhledávání: '"Robert F. Ozols"'
Autor:
Robert S. Mannel, Robert A. Burger, David S. Alberts, Daniel S. Kapp, Robert F. Ozols, Michael A. Bookman, Maurie Markman, Bradley J. Monk, James J. Java, John K. Chan, Robert C. Young, Deborah K. Armstrong, Jeffrey G. Bell, Carol Aghajanian, Katherine Fuh, William P. McGuire
Publikováno v:
Gynecologic oncology, vol 154, iss 2
PurposeTo compare patient/tumor characteristics and outcomes of Asians to Caucasian patients with epithelial ovarian cancer.MethodsAncillary data were pooled and analyzed from ten prospective randomized front-line Gynecologic Oncology Group clinical
Autor:
Robert F, Ozols
Publikováno v:
Oncology (Williston Park, N.Y.). 32(2)
Autor:
Margaret M. Steinhoff, Chunqiao Tian, Michael T. Deavers, Behnaz Behmaram, Charlotte C. Sun, Robert E. Emerson, Robert L. Coleman, Anil K. Sood, Diane C. Bodurka, Anais Malpica, Rebecca N. Baergen, David M. Gershenson, Karen H. Lu, Golnar Rasty, Robert F. Ozols, Michael J. Birrer
Publikováno v:
Cancer. 118:3087-3094
BACKGROUND: A study was undertaken to use the 2-tier system to reclassify the grade of serous ovarian tumors previously classified using the International Federation of Gynecology and Obstetrics (FIGO) 3-tier system and determine the progression-free
Autor:
Thomas C. Krivak, Maurie Markman, Deborah K. Armstrong, Robert F. Ozols, Caela Miller, Michael P. Stany, John H. Farley, Chad A. Hamilton, Mildred R. Chernofsky, G. Scott Rose, Austin Miller, G. Larry Maxwell
Publikováno v:
Gynecologic Oncology. 122:521-526
To assess the survival impact of initial disease distribution on patients with stage III epithelial ovarian cancer (EOC) cytoreduced to microscopic residual.We reviewed data from 417 stage III EOC patients cytoreduced to microscopic disease and given
Autor:
David S. Alberts, Robert L. Coleman, J. Tate Thigpen, Eric L. Eisenhauer, Gini F. Fleming, Larry J. Copeland, Thomas J. Herzog, Bradley J. Monk, Gordon J. S. Rustin, Aarati Ranganathan, Michael J. Birrer, Paula M. Fracasso, Robert F. Ozols, Maurie Markman, Mark F. Brady, Robert C. Bast, David M. Gershenson, Marissa Shrader
Publikováno v:
Clinical Ovarian Cancer. 3:81-97
Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. Although the prevalence of ovarian cancer when compared with other neoplasms is low, with an estimated 21,550 new cases in 2009, the majority
Autor:
Robert F. Ozols, Franco M. Muggia, David R. Spriggs, Peter G. Rose, Richard J. Zaino, William McGuire, Deborah K. Armstrong, Maurie Markman, Chunqiao Tian
Publikováno v:
Cancer. 115:1395-1403
There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis.A retrospec
Autor:
Chunqiao Tian, Peter G. Rose, Deborah K. Armstrong, William McGuire, Franco M. Muggia, William J. Hoskins, Robert F. Ozols, Maurie Markman, David R. Spriggs, Kristin K. Zorn
Publikováno v:
Cancer. 115:1028-1035
The objective of the current study was to determine the prognostic significance of a pretreatment serum CA 125 level in patients with advanced epithelial ovarian carcinoma (EOC) who received treatment with a standard chemotherapy regimen.Patients wit
Autor:
Lynn M. Schuchter, John W. Sweetenham, James A. Bonner, Linda T. Vahdat, George D. Demetri, Robert F. Ozols, Derek Raghavan, Allen S. Lichter, Patricia A. Ganz, Dean F. Bajorin, Barnett S. Kramer, Bruce D. Cheson, Nancy E. Davidson, Julie Gralow, Gregory H. Reaman, Maurie Markman, Robert J. Mayer, Raymond Sawaya, Scott Ramsey, Richard L. Schilsky, Howard M. Sandler, Walter J. Curran, Eric P. Winer, Mark G. Kris
Publikováno v:
Journal of Clinical Oncology. 26:313-325
A MESSAGE FROM ASCO'S PRESIDENT For the third year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most signific
Autor:
Ralph S. Freedman, Karen Basen-Engquist, Susan G. Arbuck, Lari Wenzel, Robert C. Bast, Sandra J. Horning, Richard Pazdur, Gordon J. S. Rustin, J. Tate Thigpen, Robert F. Ozols, David R. Spriggs, Laurie B. Burke
Publikováno v:
Gynecologic Oncology. 107:173-176
Objective The unique characteristics of cancer, particularly issues involving the use of surrogate endpoints in clinical trials, present special challenges in the development of cancer drugs. In response, the U.S. Food and Drug Administration (FDA) h
Autor:
William E. Winter, William McGuire, Deborah K. Armstrong, Maurie Markman, Chunqiao Tian, Peter G. Rose, Franco M. Muggia, Jay W. Carlson, Robert F. Ozols, G. Larry Maxwell
Publikováno v:
Journal of Clinical Oncology. 25:3621-3627
Purpose Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity of study population. The purpose of this study was to identify factors predictive of poor